Recent News

• 04.22.2025 - Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
• 04.03.2025 - Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries
• 03.07.2025 - Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
• 02.03.2025 - Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries
• 01.30.2025 - Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results
• 01.30.2025 - Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

Recent Filings

• 03.21.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 03.19.2025 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 03.07.2025 - EX-99.1 EX-99.1
• 03.07.2025 - 8-K Current report
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2025 - 8-K Current report